Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2019 Jul 15.
Published in final edited form as: Bioorg Med Chem Lett. 2018 May 23;28(13):2302–2313. doi: 10.1016/j.bmcl.2018.05.024

Adamantyl thioureas as soluble epoxide hydrolase inhibitors

Vladimir Burmistrov a,b, Christophe Morisseau a, Dmitry Pitushkin b, Dmitry Karlov c,d,e, Robert R Fayzullin f, Gennady M Butov b, Bruce D Hammock a,*
PMCID: PMC6442743  NIHMSID: NIHMS1521421  PMID: 29803731

Abstract

A series of inhibitors of the soluble epoxide hydrolase (sEH) containing one or two thiourea groups has been developed. Inhibition potency of the described compounds ranges from 50 μM to 7.2 nM. 1,7-(Heptamethylene)bis[(adamant-1-yl)thiourea] (6f) was found to be the most potent sEH inhibitor, among the thioureas tested. The inhibitory activity of the thioureas against the human sEH is closer to the value of activity against rat sEH rather than murine sEH. While being less active, thioureas are up to 7-fold more soluble than ureas, which makes them more bioavailable and thus promising as sEH inhibitors.

Keywords: soluble epoxide hydrolase, inhibitor, adamantine, isothiocyanate, thiourea

Graphical Abstract

graphic file with name nihms-1521421-f0001.jpg


Mammalian soluble epoxide hydrolase (sEH, E.C. 3.3.2.10) is involved in the metabolism of epoxy-fatty acids to the corresponding vicinal diols through the reaction with a water molecule.1,2 Endogenous substrates for the sEH include cytochrome P450 metabolites of arachidonic (epoxyeicosatrienoic acids, EETs) and docosahexaenoic (epoxydocosatrienoic acids, EDPEs) acids.3,4 EETs possess vasodilatory effects through the activation of the calcium dependent broad K+-channels in endothelial cells, which are beneficial in many renal and cardiovascular diseases.5,6 Furthermore, the EETs have some anti-inflammatory and analgesic properties.7 Their conversion to dihydroxyeicosatrienoic acids (DHETs) by sEH reduces those beneficial activities. The inhibition of sEH in vivo by highly selective inhibitors results in an increase of the concentration of the EETs and other epoxy fatty acids and is accompanied by a reduction in angiotensin driven blood pressure in rodents, but also reduction of inflammatory and painful states, thereby suggesting that sEH is a target for the treatment of hypertension, inflammatory diseases and pain.810

Most of compounds reported as sEH inhibitors are 1,3-disubstituted ureas.1115 To our knowledge, only 10 thioureas have been reported as sEH inhibitors16,17 compared to thousands of ureas. Thus, a systematic investigation of thioureas as sEH inhibitors is needed. Separately, ureas are difficult to formulate because of their high melting points and low water solubility. Herein, we investigate the influence of a thiourea function on the physical properties in comparison to ureas.

The common structure of known sEH thiourea based inhibitor is Ad-NHC(S)NH-R, where Ad is adamantan-1-yl, R is alkyl, aryl or heterocyclic group.1820 While the R-group was altered, the left (adamantane) part of the thiourea molecules was the same in almost all known thioureas based sEH inhibitors. Thus, the impact of alterations in adamantyl part of the thioureas on their potency and properties has never been investigated.

In this work we prepared and systematically studied new structural types of adamantyl thioureas with the following features: (i) spacers between adamantyl substituent and thiourea group to enhance conformational mobility; (ii) alkyl substituents in the bridgehead positions of adamantane to alter its lipophilicity; (iii) two adamantyl parts in a single molecule; (iv) adamantyl fragment linked with thioureas group by the bridge carbon; (v) aromatic fragments to regulate lipophilicity.

Reaction of amines with isothiocyanates is among the most widely used procedures for the preparation of thioureas. In contrast to isocyanates, isothiocyanates are less reactive and do not react with water in common conditions21. Due to the bimolecular nature of this reaction, the adamantane moiety can be introduced in to the molecule of thiourea either with adamantyl amine or with adamantyl isothiocyanate. In this case, it is reasonable to use adamantyl amines, which are quite available in contrast to the adamantyl isothiocyanates.22 Since the mechanism of thiourea formation is nucleophilic addition to thiocarbonyl group, the most significant factors affecting the reaction speed are the amine nucleophilicity, positive charge on a thiocarbonyl carbon atom and steric factors in a transition state. On the one hand, the basicity of amino group in adamantyl amines is relatively high23 due to the donor effect of adamantane fragment, which should have positive effect on reactivity. On the other hand, steric hindrance in transition state caused by large adamantane fragment could lower reactivity of such amines despite of high basicity. Introduction of spacers between the amino group and adamantane will decrease basicity as well as steric hindrance in transition state.

Previous research24 showed that selectivity of the reaction under consideration is highly affected by the reagents ratio and the solvent used. So when carrying reaction with equimolar amount of adamantyl amine or in excess of aromatic isothiocyanate, an adverse reaction leading to the formation of corresponding adamantyl isothiocyanate takes place. This metathesis effect is possible due to the consecutive route of the reaction when thioureas are involved in the reaction with excessive isothiocyanate. Hence, it is expedient to use solvents, which cannot dissolve thioureas and thereby exclude it from the reaction zone (for instance, hexanes). It is necessary to mention that metathesis of amines into isothiocyanates was discovered in reactions carried out without triethylamine.24 Introduction of strong base such as Et3N or DIPEA in most cases suppresses the adverse reaction between thioureas and isothiocyanate.

Thioureas bearing aromatic moiety are the most intensively investigated as biologically active compounds among the thioureas.2527 Combination of a benzene ring and an adamantyl fragment in one molecule is of great interest. Among ureas and thioureas containing aromatic moiety those with EWG (Cl, F, F3C and F3CO) were the most potent as sEH inhibitors.28 Taking into account that interaction of urea-type inhibitor with the sEH domain is NH-acidity dependent, we developed thioureas containing aromatic ring substituted with EWG (1j-q, Scheme 1).

Scheme 1.

Scheme 1.

Reagents and conditions: a. DMF, Et3N, 80 ºC, 12 h.

Thioureas 1a, 1d-1h are poorly soluble in water due to hydrophobic nature of both the adamantyl and aromatic sides of the molecules. Insertion of one methylene bridge between thiourea group and benzene ring leads to the 4-fold decrease in water solubility and to an increase of activity (1a vs. 1d) while addition of second one does not affect solubility and leads to a slight decrease of activity (1d vs. 1f). A 3-fluoro substituted aromatic part does not change water solubility (1j-m) while fluorine in 4-position makes the thioureas 4-fold more soluble in water (for example, 1a vs. 1n). Introduction of fluorine into the 4-position of the aromatic nucleus also leads to the most notable increase of activity. Thioureas with methyl substituents in bridgehead positions in adamantane as well as those with methylene spacers at the thiourea groups possessed lower melting points. For example, in a row of thioureas 1b, 1e and 1h introduction of methylene spacer leads to 39 ºC decrease in melting point and for another 9 ºC with a 1,2-ethylene spacer. The most significant melting point decrease (108 ºC) is observed when two 1,2-ethylene spacers were introduced at both sides of the thiourea groups when compound 1i compared to 1-(adamantan-1-yl)-3-phenyl thiourea.30 More substituents in the adamantane part of the thiourea molecule as well as complication of the spacer at thioureas group leads to lower inhibitory activity. In this case complicated spacers have the worst impact on activity decrease. Compounds 1a and 1b have the same molecular mass but 1a (no spacer between adamantane and thiourea, two methyl substituents in adamantane) is 2-fold more potent than 1b (1,1-etylene spacer between adamantane and thiourea, no substituents in adamantane). Compound 1c (-CH2-CH(C2H5)- spacer between adamantane and thiourea, no substituents in adamantane) is 25-fold less potent than 1a. Similar trend was observed for compounds 1d and 1e; 1g, 1f and 1h; 1o, 1n and 1p. The only exception from this empirical rule are the compounds with a 1,2-ethylene spacer between the adamantane and thiourea groups (1m and 1q) being more potent than thioureas with single methylene spacer (1k) or with two methyl substituents in adamantane (1n).

As previously reported, 2-adamantyl ureas usually were more potent then corresponding 1-adamantyl analogs.18 Thus, we carried out reactions of 2-adamantyl amines with aromatic isothiocyanates (Scheme 2).

Scheme 2.

Scheme 2.

Reagents and conditions: a. DMF, Et3N, 80 ºC, 12 h.

Water solubility of thioureas predictably lowers with each new methylene group between thiourea group and the benzene ring. Besides that, addition of branched spacer between the thiourea and adamantane part led to 4–9-fold decrease of solubility. For compounds 2a-c regulations concerning the effect of spacers on inhibition potency against sEH are the same as for compounds 1a-s. For compounds 2a-c inhibition potency increased 6.7-fold when a methylene spacer was added between the thiourea groups and the benzene rings (from 229 nM for compound 2a to 34 nM for 2b) and 4-fold more with 1,2-ethylene spacer (up to 8.2 nM for compound 2c). IC50 of 8.2 nM for compound 2c is extremely high activity for thioureas and even good enough for ureas.

A molecular docking in the sEH active site was performed for compounds 2a, 2b and 2c. For this, the published X-ray crystal structure of the human sEH complexed with a thioureas-based ligand (PDB accession number 4JNC) was used.31 For compounds 2b (Fig. 1) and 2c (Fig. 2) the known19 complexation model was confirmed and the potency difference between these thioureas probably is connected with their lipophilicity. The 3D depictions of the binding site (Fig. 13) were created with VIDA 4.3.0 (OpenEye Scientific Software, Santa Fe, NM http://www.eyesopen.com).

Figure 1.

Figure 1.

Compound 2b (green) docked into the active site of human sEH.

Figure 2.

Figure 2.

Compound 2c (green) docked into the active site of human sEH.

Figure 3.

Figure 3.

Compound 2a (green) docked into the active site of human sEH. Upside down orientation of the molecule and the absence of hydrogen bonds (dashed green lines) between the sulfur and Tyr383 and Tyr466 observed.

Compared to its urea analog32, 2a is 13-fold less potent. The molecular docking of 2a (Fig 3) suggests that it is twisted upside down, unlike 2b and 2c (fig. 1 & 2). In such position, there is no bonding possible between the thiourea and the protein, which probably explain 2a low inhibitory activity (Table 2). Besides 2a, such positioning in the active site could explain why thioureas were found previously to be poor sEH inhibitor16,19, as the hydrogen bonds between the chalcogen and Tyr383 and Tyr466 are essential to yield highly potent inhibitor of sEH33.

Table 2.

IC50 values and some physico-chemical properties for adamantyl-aryl sEH inhibitors 2a-c

graphic file with name nihms-1521421-t0015.jpg
a

Solubilities were measured in sodium phosphate buffer (pH 7.4, 0.1 M) containing 1% of DMSO.

b

As determined via a kinetic fluorescent assay. Results are means of three separate experiments.30

The X-ray crystal structure of compound 2a (Fig. 4) reveals that the molecule is bent against the conformation proposed above. Prevalence of this conformation could also explain the low activity of thioureas due to the difficulty of hydrogen bond formation between NH and Asp335.

Figure 4.

Figure 4.

ORTEP diagram showing 50% probability anisotropic displacement ellipsoids of non-hydrogen atoms for compound 2a according to single crystal XRD data collected at 100(2) K.

Thiourea 2a crystallizes in the monoclinic space group P21/c with one molecule in the asymmetric cell. The molecular structure of 2a in the crystalline phase is characterized by the antiperiplanar torsion angle of the С21–N2–C1–S1 moiety {τ = 173.8(3)°} and the synperiplanar angle of the С101–N1–C1–S1 moiety {τ = 7.2(5)°}. The geometry of the symmetrically independent molecule 2a is shown in Fig. 4. The main supramolecular motif in the crystals is a centrosymmetric dimer, which is formed by the intermolecular hydrogen bonds N2–Н2…S1 {N2–Н20.868(18) Å, Н2…S1 2.59(2) Å, N2…S1 3.425(3) Å, N2–Н2…S1 162(3)°; symmetry code: –x+1,–y+2,–z+1}. A potential H-bond donor group N2–Н2 has no acceptor due to steric obstacles caused by the phenyl and adamantan-2-yl substituents. The fragment of molecular packing of 2a in the crystals is presented in Fig. 5. The figure shows the significant contribution of N–Н…S and C–Н…S interactions to the stabilization of the molecular conformation. The mentioned distance Н2…S1 is shorter that the sum of the contact radii of hydrogen (1.20 А) and sulfur (1.80 А).34 The three-dimensional crystal structure is arranged by the association of the zero-dimensional dimers by weak dispersion interactions of the peripheral fragments. The packing index is equal to 67.9 %. The crystallographic data for the investigated compound have been deposited in the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 1824337.

Figure 5.

Figure 5.

Fragment of the molecular packing in the crystals 2a viewed along the axis 0c according to XRD. Intermolecular interactions N–Н…S and C–Н…S are marked in green and magenta dotted lines, respectively.

It was previously showed that 1,3-disubstituted ureas with two adamantyl fragments in their structure are very potent soluble epoxide inhibitors.17 We used adamantyl isothiocyanates along with adamantyl amines to synthesize diadamantyl thioureas 3a-j, 4a-f and 5 (Scheme 35).

Scheme 3.

Scheme 3.

Reagents and conditions: a. DMF, Et3N, 80 ºC, 12 h.

Scheme 5.

Scheme 5.

Reagents and conditions: a. DMF, Et3N, 80 ºC, 12 h.

Diadamantyl thioureas could be divided into three groups based on connection of adamantane with thioureas group. In thioureas 3a-j both adamantanes linked with thiourea group by its bridgehead carbons while in thioureas 4a-f one adamantane linked with its bridgehead carbon and second with bridge carbon. In compound 5 both adamantanes linked with thioureas by its bridge carbons.

Thioureas with two adamantyl fragments with some exceptions possess water solubility of 30–120 µM and inhibitory potency up to 11.2 nM. Intramolecular interactions in symmetrical molecules are relatively high, and therefore introduction of methylene spacer between adamantyl and thiourea group increases solubility (3a-c) but has almost no effect on activity. A 1,4- phenylene spacer in the same position does not affect water solubility (3a and 3e or 3c and 3g) but dramatically decreases inhibitory activity against the sEH. Introduction of two 1,4-phenylene spacers from both sides of thiourea group leads to 3-fold increase in water solubility accompanied with 1367-fold decrease in inhibition potency (3a vs. 3j). It should be noted that synthesized thioureas are 4–5-fold more water soluble than ureas of corresponding structure. For example diadamantyl thiourea 3a is 4.7-fold more soluble than corresponding diadamantyl urea.17

Interestingly, quantum chemical calculations for DAU and 3a indicate that the presence of the sulfur atom in place of the oxygen in DAU yields a change in conformation of the chemicals. As shown on Fig 6, while conformer A is the most stable for DAU, conformer C is the preferred form of 3a (MP2, def2-SVP, Orca 4.0.137). This could in part explain the difference in potency observed between DAU and 3a.

Figure 6.

Figure 6.

The conformers of the di(adamantan-1-yl)urea and thiourea used in quantum chemical calculations.

Thus, in some cases loss of potency for thioureas in comparison with the ureas can be explained by the change in the conformational population.

The impact of asymmetry combined with the ability of the molecule to create intramolecular hydrogen bonds could be traced on thioureas 3a, 4a and 5. These three thioureas have two adamantyl fragments directly linked with thiourea group without any spacers or substituents. Only difference is the connection between adamantyl and thiourea group in compound 3a, where both adamantyls are linked by bridgehead carbons, whereas in compound 5, both the adamantyls are linked by bridge carbons. Similarly in compound 4a, one is linked by bridge carbon whereas the other one by bridgehead. Thiourea 5 is 1.5-fold more soluble than thiourea 3a while asymmetric thiourea 4a is 1.8-fold more soluble than 3a.

Previously, we reported that diureas containing two urea groups linked with aliphatic spacer are very potent soluble epoxide hydrolase inhibitors.18 High activity of these compounds supposed to be due to the ability of second urea group to bind with Ser374 of the sEH while the second adamantyl contacts the inner hydrophobic areas of the protein.

Synthesis of symmetric dithioureas was carried out by the reaction of 1- adamantylisothiocyanate with aliphatic diamines (Scheme 6).

Scheme 6.

Scheme 6.

Reagents and conditions: a. DMF, Et3N, 80 ºC, 12 h.

Water solubility of dithioureas decreases with each new methylene group introduced between thiourea groups and there is 3-fold difference between compound 6a with 1,2-ethylene spacer and compound 6h with 1,10-decylene. Thiourea 6a is 10–137-fold less potent than the rest of thioureas in this series. Such a big difference support our hypothesis about formation of hydrogen bonds between second thiourea group and Ser374 and propylene linker is the required minimum while 6–8 carbon linkers preferred. When extending spacer between thiourea groups inhibition potency grows and comes to a maximum of 7.2 nM with 1,7-heptylene spacer (6f). Further elongation leads to a slight decrease of activity.

Trying to compare water solubility of our adamantyl thioureas with known ureas of corresponding structure, we discovered the lack of such data in the literature. Thus we synthesized four dithioureas 6i-l similar to the diureas with known water solubility (Table 6).

Table 6.

Water solubility of thioureas compared to ureas of similar structure

graphic file with name nihms-1521421-t0018.jpg
a

Solubilities were measured in sodium phosphate buffer (pH 7.4, 0.1 M) containing 1% of DMSO.

Data in Table 6 show that thioureas are 2.5–7-fold more soluble in water than ureas of similar structure. Despite of lesser inhibition potency against human sEH than ureas, thioureas more soluble in water. Thus, the total effectiveness of thioureas when compared to ureas seems to be on the same level with the correct approach to the design of the molecule.

During the transition from in vitro testing to in vivo, first series usually carried out on laboratory animals, specifically mice and rats. To confirm extrapolation possibility of rodent in vivo testing to humans, we investigated inhibition potency of thioureas against mouse and rat sEH (Table 7).

Table 7.

Inhibitory potency of thioureas 2a, 2c, 2e, 6b-6h against human (hsEH), rat (rsEH) and murine (msEH) soluble epoxide hydrolases

graphic file with name nihms-1521421-t0019.jpg
a

As determined via a kinetic fluorescent assay. Results are means of three separate experiments.30

Data (Table 7) show that thioureas in general are less active against rodent sEH. Therefore, one must be careful while transferring the effects found in vivo on rodents to humans. In addition, in most cases, the inhibitory activity of thioureas against the human sEH is closer to the value of activity against rat sEH rather than murine sEH. Therefore, it is advisable to conduct in vivo sEH inhibition tests on laboratory rats.

Thus, a series of thioureas and dithioureas has been developed and systematic study of adamantyl thioureas as inhibitors of the soluble epoxide hydrolase (sEH) was performed. Inhibition potency of the described compounds ranges from 50 μM to 7.2 nM. Among the thioureas, compound 2c (IC50 = 8.2 nM) and compound 6f (IC50 = 7.2 nM) were found to be the most potent sEH inhibitors. While being less potent, the thioureas are up to 7-fold more soluble than the corresponding ureas, suggesting the sulfur containing compounds could be easier to formulate and probably more bioavailable than the corresponding ureas.

Supplementary Material

1

Scheme 4.

Scheme 4.

Reagents and conditions: a. DMF, Et3N, 80 ºC, 12 h.

Table 1.

IC50 values and some physico-chemical properties for adamantyl-aryl sEH inhibitors 1a-q

graphic file with name nihms-1521421-t0014.jpg
a

Solubilities were measured in sodium phosphate buffer (pH 7.4, 0.1 M) containing 1% of DMSO.

b

As determined via a kinetic fluorescent assay. Results are means of three separate experiments.30

Table 3.

IC50 values and some physico-chemical properties for adamantyl-aryl sEH inhibitors 3a-j, 4a-f and 5

graphic file with name nihms-1521421-t0016.jpg
a

Solubilities were measured in sodium phosphate buffer (pH 7.4, 0.1 M) containing 1% of DMSO.

b

As determined via a kinetic fluorescent assay. Results are means of three separate experiments.29

c

DAU: 1,3-diadamantyl urea

Table 4.

The relative conformational energies for di(adamantan-1-yl)urea and di(adamantan-1yl)thiourea compared with the conformer of the lowest energy (kcal/mol)

X Conformer A Conformer B Conformer C
X = O 0 6.2 2.8
X = S 0.3 4.2 0

Table 5.

IC50 values and some physico-chemical properties for adamantyl-aryl sEH inhibitors 6a-h

graphic file with name nihms-1521421-t0017.jpg
a

Solubilities were measured in sodium phosphate buffer (pH 7.4, 0.1 M) containing 1% of DMSO.

b

As determined via a kinetic fluorescent assay. Results are means of three separate experiments.30

Thioureas with agrdamantane fragment were systematically studied as sEH inhibitors.

45 adamantyl thioureas were synthesized.

Difference of activity against human, rat and murine sEH were investigated.

Discovered that thioureas are up to 7-fold more soluble than corresponding ureas.

Acknowledgments

This work was supported by Russian Fund for Basic Research (grant number 16–33- 00172) and by the Ministry of Education and Science of the Russian Federation (base part of state assignment for 2017–2019; project no. 4.7491.2017/BCh), National Institute of Environmental Health Sciences (NIEHS) grant R01 ES002710, and NIEHS Superfund Research Program grant P42 ES004699.

The authors would like to thank the OpenEye Scientific Software Company for the academic license for their software.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • 1.Arand M; Grant DF; Beetham JK; Friedberg T; Oesch F; Hammock BD FEBS Lett 1994, 338, 251. [DOI] [PubMed] [Google Scholar]
  • 2.Oesch F Xenobiotica 1973, 3, 305. [DOI] [PubMed] [Google Scholar]
  • 3.Zeldin DC; Kobayashi J; Falck JR; Winder BS; Hammock BD; Snapper JR; Capdevilla JH J. Biol. Chem 1993, 268, 6402. [PubMed] [Google Scholar]
  • 4.Spector AA; Fang X; Snyder GD; Weintraub NL Prog. Lipid Res 2004, 43, 55. [DOI] [PubMed] [Google Scholar]
  • 5.Fleming I; Rueben A; Popp R; Fisslthaler B; Schrodt S; Sander A; Haendeler J; Falck JR; Morisseau C; Hammock BD; Busse R Arterioscler. Thromb Vasc. Biol 2007, 27, 2612. [DOI] [PubMed] [Google Scholar]
  • 6.Imig JD Expert Opin. Drug Metab. Toxicol 2008, 4, 165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Yu Z; Xu F; Huse LM; Morisseau C; Draper AJ; Newman JW; Parker C; Graham L; Engler MM; Hammock BD; Zeldin DC; Kroetz DL Circ. Res 2000, 87, 992. [DOI] [PubMed] [Google Scholar]
  • 8.Spiecker M; Liao JK Arch. Biochem. Biophys 2005, 433, 420. [DOI] [PubMed] [Google Scholar]
  • 9.Imig JD; Zhao X; Capdevilla JH; Morisseau C; Hammock BD Hypertension 2002, 39, 690. [DOI] [PubMed] [Google Scholar]
  • 10.Imig JD; Zhao X; Zaharis CZ; Olearczyk JJ; Pollock DM; Newman JW; Kim IH; Watanabe T; Hammock BD Hypertension 2005, 46, 975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Garscha U; Romp E; Pace S; Rossi A; Temml V; Schuster D; König S; Gerstmeier J; Liening S; Werner M; Atze H; Wittmann S; Weinigel C; Rummler S; Scriba GK; Sautebin L; Werz O Scientific Reports 2017, 7, 9398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Dong X; Jia Y; Gea I; Jiang B; Jiang J; Shen J; Jin Y; Guan Y; Sun Y; Xie Q Toxicology 2017, 389, 31. [DOI] [PubMed] [Google Scholar]
  • 13.Kitamura S; Morisseau C; Harris TR; Inceoglu B; Hammock BD PLOS ONE 2017, 12(5): e0176571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Meirer K; Glatzel D; Kretschmer S; Wittmann SK; Hartmann M; Blöcher R; Angioni C; Geisslinger G; Steinhilber D; Hofmann B; Fürst R; Proschak E Molecules 2017, 22, 45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Manickam M; Pillaiyar T; Boggu PR; Venkateswararao E; Jalani HB; Kim N; Lee SK; Jeon JS; Kim SK; Jung S Eur. J. Med. Chem 2016, 117, 113. [DOI] [PubMed] [Google Scholar]
  • 16.McElroy NR; Jurs PC; Morisseau C; Hammock BD J. Med. Chem 2003, 46, 1066. [DOI] [PubMed] [Google Scholar]
  • 17.Anandan S-K; Do ZN, Webb HK; Patel DV; Gless RD Bioorg Med Chem Lett 2009, 19, 1066. [DOI] [PubMed] [Google Scholar]
  • 18.Burmistrov V; Morisseau C; Lee KSS; Shihadih DS; Harris TR; Butov GM; Hammock BD Bioorg Med Chem Lett 2014, 24, 2193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Hwang SH; Tsai HJ; Liu JY; Morisseau C; Hammock BD J. Med. Chem 2007, 50, 3825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Kim IH; Morisseau C; Watanabe T; Hammock BD J. Med. Chem 2004, 47, 2110. [DOI] [PubMed] [Google Scholar]
  • 21.Morisseau C; Goodrow MH; Dowdy D; Zheng J; Greene JF; Sanborn JR; Hammock BD Proc. Natl. Acad. Sci. USA 1999, 96, 8849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Waterman C; Cheng DM; Rojas-Silva P; Poulev A; Dreifus J; Lila MA; Raskin I Phytochemistry 2014, 103, 114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Burmistrov VV, Butov GM, Pitushkin DA Russ. J. Org. Chem 2015, 51, 1795. [Google Scholar]
  • 24.Hoshino Y; Shimbo Y; Ohtsuka N; Honda K Tetrahedron Lett 2015, 56, 710. [Google Scholar]
  • 25.Burmistrov V; Pitushkin D; Butov G SynOpen 2017, 1, 121. [Google Scholar]
  • 26.Tsypysheva IP; Koval’skaya AV; Lobov AN; Salimgareeva MK; Fatkullina US; Petrova PR; Gabdrakhmanova SF; Makara NS; Suponitskii KY; Vakhitova YV; Zarudii FS; Yunusov MS Chemistry of Natural Compounds 2013, 49, 707. [Google Scholar]
  • 27.Spilovska K; Korabecny J; Kral J; Horova A; Musilek K; Soukup O; Drtinova L; Gazova Z; Siposova K; Kuca K Molecules 2013, 18, 2397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Saeed A; Ashraf Z; Erben MF; Simpson JJ Mol. Struct 2017, 1129, 283. [Google Scholar]
  • 29.Hwang SH; Wecksler AT; Zhang G; Morisseau C; Nguyen LV; Fu SH; Hammock BD Bioorg. Med. Chem. Lett 2013, 23, 3732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Jones PD; Wolf NM; Morisseau C; Whetstone P; Hock B; Hammock BD Anal. Biochem 2005, 343, 66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Al-Wahaibi LH; Ghabbour HA; Mostafa GAE; Almutairi MS; El-Emam AAZ Kristallogr. NCS 2016, 231, 593. [Google Scholar]
  • 32.Thalji RK; McAtee JJ; Belyanskaya S; Brandt M; Brown GD; Costell MH; Ding Y; Dodson JW; Eisennagel SH; Fries RE; Gross JW; Harpel MR; Holt DA; Israel DI; Jolivette LJ; Krosky D; Li H; Lu Q; Mandichak T; Roethke T; Schnackenberg CG; Schwartz B; Shewchuk LM; Xie W; Behm DJ; Douglas SA; Shaw AL; Marino JP Bioorg. Med. Chem. Lett 2013, 23, 3584. [DOI] [PubMed] [Google Scholar]
  • 33.Kasagami T; Kim I-H; Tsai H-J; Nishi K; Hammock BD; Morisseau C Bioorg. Med. Chem. Lett 2009, 19, 1784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Morisseau C; Hammock BD Annu. Rev. Pharmacol. Toxicol 2005, 45, 311–333. [DOI] [PubMed] [Google Scholar]
  • 35.Bondi AJ Phys.Chem, 1964, 68, 441. [Google Scholar]
  • 36.Eguchi S; Takeuchi H; Watanabe N Nippon Kagaku Kaishi 1987, 7, 1280. [Google Scholar]
  • 37.Neese F WIREs Comput. Mol. Sci 2012, 2, 73. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES